Futura Medical PLC's (LON:FUM) CEO James Barder tells Proactive London they're on track to deliver the results from their phase III trial for a fast-acting gel for erectile dysfunction (ED) by the end of the year.
The first of two studies of MED2005 got underway in October treating 1,000 men at 60 centres across Europe.
A recent shift in strategy at Futura's seen them now focus attention firmly on MED2005, the ED treatment and TPR100, a topical non-steroidal anti-inflammatory and pain killer.
